EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases

Nutchaya Sukon, Pitipol Choopong, Usanee Tungsattayathitthan, Nattaporn Tesavibul, Wilawan Sanpan, Sutasinee Boonsopon

International Ophthalmology · 2024

DOI: 10.1007/s10792-024-02980-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Ophthalmology, 2024. Verfasst von Nutchaya Sukon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Scleritis, Uveitis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate for association between skin autofluorescence (SAF) advanced glycation end products (AGEs) and uveitis/scleritis activity in systemic inflammatory disease-related active non-infectious uveitis/scleritis patients.

Methods

This cross-sectional study was conducted at Siriraj Hospital during October 2019 to March 2020. AGEs were measured by SAF method in systemic immune-related disease patients with active uveitis/scleritis, and those results were compared with those of healthy age-matched controls.

Results

Thirty-one active non-infectious uveitis/scleritis patients and 31 age-matched controls were enrolled. The mean age of patients was 40.0 ± 12.8 years, and most were female (55.0%). The most common associated systemic immune-related disease was Vogt–Koyanagi–Harada disease ( n = 14). Mean SAF AGE level in the study group compared to the control group was 2.38 ± 0.66 arbitrary units (AU) versus 2.58 ± 0.56 AU, respectively ( p = 0.20). Multivariate analysis showed decreased SAF AGE level to be significantly associated with active ocular inflammation, (odds ratio: 0.01, 95% confidence interval: 0.00004–0.81; p = 0.04).

Conclusions

SAF AGE level was not so far found to be a reliable biomarker for indicating uveitis/scleritis activity in systemic immune-related disease patients with active ocular inflammation. Clinical trial registration Thai Clinical Trials Registry, https://www.thaiclinicaltrials.org/ . (Reg. No. TCTR20200114004, registered date 01/01/2020, beginning date of the trial 10/01/2019).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ScleritisUveitisAdultFemaleHumansMaleMiddle AgedCross-Sectional StudiesGlycation End Products, AdvancedInflammation

Stichwörter der Autor:innen

AGEsAdvanced glycation end productsBiomarkerScleritisUveitis

Substanzen

Glycation End Products, Advanced

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. sutasinee.boo@mahidol.edu.

Zitieren

APA

Sukon, N., Choopong, P., Tungsattayathitthan, U., Tesavibul, N., Sanpan, W., & Boonsopon, S. (2024). Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases. International Ophthalmology. https://doi.org/10.1007/s10792-024-02980-7

Vancouver

Sukon N, Choopong P, Tungsattayathitthan U, Tesavibul N, Sanpan W, Boonsopon S. Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases. International Ophthalmology. 2024. doi:10.1007/s10792-024-02980-7

BibTeX
@article{Sukon2024,
  author = {Sukon, Nutchaya and Choopong, Pitipol and Tungsattayathitthan, Usanee and Tesavibul, Nattaporn and Sanpan, Wilawan and Boonsopon, Sutasinee},
  title = {Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases},
  journal = {International Ophthalmology},
  year = {2024},
  doi = {10.1007/s10792-024-02980-7}
}
Kostenlos starten →